Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: A randomized controlled trial employing proton magnetic resonance spectroscopy

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 10, 2009, Pages 3842-3848

  Cussons, Andrea J ^a,c   Watts, Gerald F ^a   Mori, Trevor A ^a   Stuckey, Bronwyn G A ^a,b,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Keogh Institute for Medical Research   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; OLIVE OIL; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAT CONTENT; FATTY LIVER; FEMALE; HUMAN; LIPID BLOOD LEVEL; MARINE SPECIES; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

EID: 70349902776     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0870     Document Type: Article

References (37)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. Fertil Steril 91:456-488
2. Ehrmann DA 2005 Polycystic ovary syndrome. N Engl J Med 352: 1223-1236
3. Cussons AJ, Stuckey BG, Watts GF 2006 Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185:227-239 (Pubitemid 43306732)
4. Setji TL, Holland ND, Sanders LL, Pereira KC, Diehl AM, Brown AJ 2006 Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91:1741-1747
5. Schwimmer JB, Khorram O, Chiu V, Schwimmer WB 2005 Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 83:494-497 (Pubitemid 40221817)
6. Cerda C, Pérez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir- Petermann T, Espinoza M, Pizarro M, Solis N, Miquel JF, Arrese M 2007 Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 47:412-417 (Pubitemid 47176161)
7. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W 2007 Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 5:496-501 (Pubitemid 46575354)
8. Brzozowska MM, Ostapowicz G, Weltman MD 2009 An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 24:243-247
9. Angulo P 2002 Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231
10. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J 2002 NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379 (Pubitemid 34106377)
11. Bellentani S, Bedogni G, Tiribelli C 2008 Liver and heart: a new link? J Hepatol 49:300-302
12. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL 2005 Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.Am J Physiol Endocrinol Metab 288:E462-E468
13. Clark JM, Brancati FL, Diehl AM 2002 Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657
14. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE 2004 Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39:1647-1654
15. Gan SK, Adams LA, Watts GF 2008 The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. Curr Opin Lipidol 19: 592-599
16. Alwayn IP, Andersson C, Zauscher B, Gura K, Nosé V, Puder M 2005 Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation 79:606-608 (Pubitemid 40365891)
17. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A 2006 Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23:1143-1151 (Pubitemid 43779354)
18. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F 2008 Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 40:194-199 (Pubitemid 351181793)
19. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW 2008 Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 14: 6395-6400
20. Mori TA, Beilin LJ 2004 Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6:461-467
21. Mori TA 2004 Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep 9:193-197 (Pubitemid 39462147)
22. Zawadski JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Boston: Blackwell; 337-384
23. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
24. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
25. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H 2000 Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758 (Pubitemid 30339990)
26. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-1395 (Pubitemid 39657013)
27. Chan DC, Watts GF, Ng TW, Hua J, Song S, Barrett PH 2006 Measurement of liver fat by magnetic resonance imaging: relationships with body fat distribution, insulin sensitivity and plasma lipids in healthy men. Diabetes Obes Metab 8:698-702 (Pubitemid 44515568)
28. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S 2008 Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134:424-431 (Pubitemid 351173050)
29. Bradbury MW, Berk PD 2004 Lipid metabolism in hepatic steatosis. Clin Liver Dis 8:639-671, xi
30. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ 2008 Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197:12-24
31. Jump DB 2008 N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol 19:242-247
32. Kelley DS, Siegel D, Vemuri M, Mackey BE 2007 Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 86:324-333 (Pubitemid 47256914)
33. Qi K, Fan C, Jiang J, Zhu H, Jiao H, Meng Q, Deckelbaum RJ 2008 Omega-3 fatty acid containing diets decrease plasma triglyceride concentrations in mice by reducing endogenous triglyceride synthesis and enhancing the blood clearance of triglyceride-rich particles. Clin Nutr 27:424-430
34. Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, Bell-Anderson KS, Farrell GC 2008 Activation of peroxisome proliferator- activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 23:267-275
35. Mori TA 2006 Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 33:842-846 (Pubitemid 44215141)
36. Targher G, Marra F, Marchesini G 2008 Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947-1953
37. Cussons AJ, Watts GF, Stuckey BG 28 March 2009 Dissociation of endothelial function and arterial stiffness in non-obese women with PCOS. Clin Endocrinol (Oxf) 10.1111/j.1365-2265.2009.03598.x